Lv4
620 积分 2023-02-04 加入
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
3个月前
已完结
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
3个月前
已完结
Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis
3个月前
已完结
Reply to: “Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed”
4个月前
已完结
Immunotherapies for hepatocellular carcinoma
4个月前
已完结
Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma
4个月前
已关闭
Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma
4个月前
已完结
Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases
4个月前
已完结
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects
4个月前
已完结
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta‐analysis
4个月前
已完结
皖公网安备34019202002308
